Intraoperative Application Experience of VIIa Recombinant Human Factor in Patients with ITP and Complicated Subdural Hematoma

M.I. Yeghiazaryan, L.A. Museyan, R.V. Fanardjian, T.N. Khachatryan, M.V. Jilavyan

University Clinical Hospital “Heratsi”, Yerevan, Armenia

Idiopathic thrombocytopenic purpura is known as the primary immune or autoimmune thrombocytopenic purpura represents the isolated immunomedi- 
dated thrombocytopenia [11, 18] on the background of 
marrow normal function [20].

The disease is often revealed in women (72%) and 
in children until 10 years (40%) [20].

Numerous clinical researches have been shown 
that the reason of the ITP development is the disintegra-
tion of thrombocytes as a result of their phagocy-
tosis antithrombocyte antibodies [11]. In the given 
process T-lymphocytes take immediate part (CD4+) 
[8, 27], having the right cytotoxic influence on throm-
bocytes [24]. Besides, the patients with ITP CD3+ lim-
phocytes can change the genes expression connected 
with apoptosis. In the result of CD3+ limphocytes can get fastness to corticosteroid therapy [23].

This classical theory, explaining ITP pathophisi-
ology (antibodies synthesis against glycoproteids of a 
cytoplasmatic membrane of thrombocytes-GPIIb-IIIa, 
GPIb-IX и GPIa-Iia – with their subsequent recogni-
tion Fcγ-thrombocytic receptors of macrophages and phagocytes) is considered old one nowadays [16, 18].

It is proved that disease can develop in 10–20% of 
cases in spite of antibodies formation process. Accord-
ing to other concept, the synthesis of the deformed 
thrombocytes by megacaryocytes and-or blockade of 
thrombocytes production provoke antithrombocytic 
antibodies [19].

In the ITP pathogenesis a special significance has 
the cytokines liberation disturbance, shown by activa-
tion Th0/Th1 of cells. As a result concentration IL-2 
and IFN-g increases, but level IL-10 goes down, up to a 
total disappearance [6, 21].

The great interest represents the research of clinical 
role CD8+ reactive cytotoxic cells concerning the 
thrombocytes which existence has been proved lately 
[19].

At ITP exacerbation, the clinical picture of the 
disease is expressed by dermal petechias eruption, 
cyanosis of mucosas in a kind of purpura, hypodermic 
hematomas, nasal bleedings, and plentiful menstrua-
tions [18]. From all possible complications intracranial 
and subarachnoidal hemorrhages are most life-threat-
ening [20].

Due to the ITP diagnostics, a particular interest 
represents the thrombocytopenia picture (thrombo-
cytes <100×10^9/l) [11] in the absence of a massive 
bleeding or an immune hemolysis on the background 
of normal indicators of a hemogram [14].

Nowadays 3 basic approaches of the ITP treat-
ment are known [14, 22, 29]. However, in complica-
tions and massive hemorrhage, besides the basic 
treatment, the acceptance of emergency measures 
according to the references of the American society of 
hematologists [5], which consist in the appointment 
of high glucocorticoids, intravenous usage of immu-
oglobulin and platelet concentrate transfusion are 
necessary. The mechanism of glucocorticoids action 
in ITP isn’t definitively found out; however there are 
the data confirming their influence on the reduction of 
synthesis of antithrombocytic antibodies, the depres-
sion of thrombocytes integration and wall capillaries 
strengthening [10].

The positive result by immunoglobulin treat-
ment is caused by temporary suppression of reticulo-
endothelial system function, so-called “blockade of 
macrophages” [2, 17]. In the modern literature there is 
a disputable question on the transfusion necessity of a 
platelet concentrate.Undoubtedly, in the case of mas-
sive hemorrhage, the given tactics provides short-term 
haemostatic effect. According to a series of authors 
[12, 15, 28], in patients with ITP, a massive bleeding 
at concentration of thrombocytes <20×10^9/l doesn’t 
form the basis for carrying out a specific therapy with- 
out fail since it can lead to deterioration of the basic 
pathology [25]. In such cases it is offered to prescribe 
NovoSeven – recombinant human factor VIIa (Novo-
Seven, Novonordisk, Denmark) [7, 9, 13, 26, 31] 
which is a preparation of a choice for urgent patients 
with a bleeding [30]. The mechanism of preparation 
efficacy consists in the connection of recombinant
human factor VIIα with the liberated tissue factor. The given complex activates factors IX, IXα, X and Xα. As a result there is a primary transformation of insignificant quantity of a prothrombin into thrombin which activates thrombocytes in the damage zone, factors V and VIII and, transforming a fibrinogen in fibrin, providing the formation of a haemostatic stopper.

To assume efficiency of this factor at disorder of a coagulative hemostasis, the patients with hemophilia have been allowed to apply the given preparation. The therapy of the Novo Seven preparation doesn't demand laboratory control. Lately, this preparation has been successfully used for treatment of bleeding which has no connections with hemophilia, namely in patients with liver function disturbances, at liver transplantation, and also for treatment of bleeding caused by an operative intervention and trauma [1]. There are data on high hemostatic efficiency of the Novo Seven preparation in the complex infusionally-transfusion therapy of a massive postnatal bleeding that testifies the expediency of its application of massive bleeding at obstetrics in childbirth-women with hemostasis pathology [3]. The preparation application in childbirth- women with ITP has allowed to refuse from the uteri extirpation and to keep reproductive function of women [4]. In the literature there is data about sufficient efficiency of the Novo Sevena appointment at subarachnoidal and parenchymatous hemorrhages [30].

We offer the results of the private experience on intraoperative applications of recombinant human factor VIIα in patients with ITP and complicated subdural hematoma.

The woman of 65 years was admitted with the complaints of headache, diplopia, the general delicacy and fatigability. According to her opinion the patient is ill within 15 days. Due to the anamnesis, the patient was administered prednizalon (120 mg/per day), strumectomy (eutirolin, 5 mg/per day). The treatment was interrupted the last month. On the basis of objective examination at the moment of admission: the consciousness – clear, arterial pressure – 110/70 mm Hg, pulse – 100/minute, breath – independent, the frequency of respiratory movements – 14/minute. With the help of auscultation the lungs were defined vesicular breath, the lien wasn't palpated, the liver was located under a costal arch. In the neurologic status positive meningeal symptoms, disturbance of functions oculomotor and abducing nerves at the left, moderated tetra paresis with positive Babinsky symptom and increasing tendinous reflexes were revealed.

While carrying out MRI (fig. 1) and CT (fig. 2) of the brain it was revealed a number of bilateral, convexital, chronic, subdural hematomas with signs of fresh repeated hemorrhage, as well as bilateral chronic subdural hematomas in the field of hemispheres of a cerebellum and mosto-cerebullum angle at the left.

The results of laboratory blood analyses were in norm limits, except for the concentration of thrombocytes which made up of 5×10^9/l.

Neurosurgeons came to the conclusion about the necessity of carrying out an operative intervention for the purpose of bilateral subdural hematomas ectomia through dilated cutter apertures.

The preparation for surgery included the prednizalon therapy (120 mg/per day) in the result on the third day there was the increasing thrombocytes level of blood up to 26×10^9/l that had the basis for an urgent operation.

Before the anesthetic induction of the patient, the analog of the Novo Sevena preparation – the Eptakogalpha (4.8 mg) was applied. Anesthesia proceeded without complications. The hemorrhage made up less than 500 ml that was the basis for the refusal of blood
transfusion preparations. In the intraoperitive period it was not observed complications in the form of the lowered blood coagulability and bleeding. After the operation the patient was exuberated and transmitted into the intensive care ward. The postoperative period proceeded without complications. Within ten days the level of thrombocytes increased up to $255 \times 10^9/l$. Wounds became healthy by the first intention, progressive disappearance of complaints and disturbances of neurologic character (fig. 3) were perceptible. The patient was discharged from the hospital in a satisfactory condition.

**REFERENCES**

1. Леменева Н. В. Терапия и профилактика операционной кровопотери при нейрохирургических вмешательствах у детей./ Автореферат диссертации на соискание степени кандидата медицинских наук. 2008

2. Петров В.Ю. Современные аспекты этногенеза, клинического течения и терапии строй тромбоцитопенической пурпуры у детей. // Автореф. дисс. ... докт. мед. наук. М., 2005.

3. Рогачевский О.В., Пучко Т.К., Фотеева Т.С. Опыт использования рекомбинантного фактора коагуляции VIIa (НовоСвен) в комплексной терапии массивного кровотечения у родильниц с идиопатической тромбоцитопенической пурпурой. Материалы Конгресса «II Всероссийский конгресс Анестезия и реанимация в акушерстве и неонатологии». Москва. 24—27 ноября 2009 г., стр. 180—181


20. Michael A Silverman, MD; Chief Editor: Pamela L Dyne, MD; Idiopathic thrombocytopenic purpura; Medscape reference; Jan 21, 2011


30. Vyhovs’ka IaI, Karol’ IuS, Fedak LM, Tsytysyk OI; pubmed article: Use of recombinant activated factor VII (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchymatous hemorrhage